Share This Article:

A Composite Endpoint Measure to Consolidate Multidimensional Impact of Treatment on Gouty Arthritis

Abstract Full-Text HTML Download Download as PDF (Size:119KB) PP. 159-164
DOI: 10.4236/ojra.2013.33024    3,714 Downloads   5,473 Views   Citations

ABSTRACT

Objective: To create a multidimensional composite outcomes endpoint for gouty arthritis treatment in order to consolidate disparate measures of comparative effectiveness. Methods: One solution is to create a multidimensional composite endpoint that consolidates the complexity of outcomes into a single scale, as was done in this study. The psychometrics of the multidimensional scale and subgroup differences were investigated. Results: Cronbach’s alpha for the multidimensional composite endpoint created in this study was 0.76, indicating good internal reliability. Similar results were found across age, race, and gender. Removing any single item did not increase Cronbach’s alpha beyond 0.77, indicating that none of the items were interfering with the reliability of the scale. However, a reduction in serum urate levels was not significantly correlated with the overall multidimensional endpoint scale with that variable removed, r = 0.03, p > 0.05. Conclusion: This study demonstrated the feasibility and usefulness of creating a composite multidimensional endpoint for assessing treatment outcomes among individuals with gouty arthritis.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

A. Sarkin, A. Gnanasakthy, R. Lale, K. Choi and J. Hirsch, "A Composite Endpoint Measure to Consolidate Multidimensional Impact of Treatment on Gouty Arthritis," Open Journal of Rheumatology and Autoimmune Diseases, Vol. 3 No. 3, 2013, pp. 159-164. doi: 10.4236/ojra.2013.33024.

References

[1] K. M. Jordan, J. S. Cameron, M. Snaith, W. Zhang, M. Doherty, J. Seckl, A. Hingorani, R. Jaques and G. Nuki, “British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout,” Rheumatology, Vol. 46, No. 8, 2007, pp. 1372-1374. doi:10.1093/rheumatology/kem056a
[2] W. Zhang, M. Doherty, T. Bardin, E. Pascual, V. Basrkova, P. Conghan, P. J. Gerster, J. Jacobs, B. Leeb, F. Lioté, G. McCarthy, P. Netter, G. Nuki, F. Perez-Ruiz, A. Pignone, J. Pimentao, L. Punzi, E. Roddy, T. Uhliq and I. Zimmermann-Gòrska, “EULAR Evidence Based Recommendations for Gout. Part II: Management. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ES-CISIT),” Annals of Rheumatic Diseases, Vol. 65, No. 10, 2006, pp. 1312-1324. doi:10.1136/ard.2006.055269
[3] T. Neogi, “Clinical Practice. Gout,” New England Journal of Medicine, Vol. 364, No. 5, 2011, pp. 443-452. doi:10.1056/NEJMcp1001124
[4] H. El-zawawy and B. F. Mandell, “Managing Gout: How Is It Different in Patients with Chronic Kidney Disease?” Cleveland Clinic Journal of Medicine, Vol. 77, No. 12, 2010, pp. 919-928. doi:10.3949/ccjm.77a.09080
[5] S. J. Lee, R. Terkeltaub, D. Khannam, J. A. Singhm A. J. Sarkin and A. Kavanaugh, “Perceptions of Disease and Health-Related Quality of Life among Patients with Gout,” Rheumatology, Vol. 48, No. 5, 2009, pp. 582-586. doi:10.1093/rheumatology/kep047
[6] J. D. Hirsch, R. Terkeltaub, D. Khanna, J. Singh, A. Sarkin, M. Shieh, A. Kavanaugh and S. J. Lee, “Impact of Gout on Health Related Quality of Life and the Relationship to Gout Characteristics,” Patient Related Outcome Measures, Vol. 1, 2010, pp. 1-8. doi:10.2147/PROM.S8310
[7] J. Sarkin, A. E. Levack, M. M. Shieh, A. F. Kavanaugh, D. Khanna, J. A. Singh, R. A. Terkeltaub, S. J. Lee and J. D. Hirsch, “Predictors of Doctor-Rated and Patient-Rated Gout Severity: Gout Impact Scales Improve Assessment,” Journal of Evaluation in Clinical Practice, Vol. 16, No. 6, 2010, pp. 1244-1247. doi:10.1111/j.1365-2753.2009.01303.x
[8] J. J. Wildfire, P. J. Gergen, C. A. Sorkness, H. E. Mitchell, A. Calatroni, M. Kattan, S. J. Szefler, S. J. Teach, G. R. Bloomberg, R. A. Wood, A. H. Liu, J. A. Liu, J. A. Pongracic, J. F. Chmiel, K. Conroy, Y. Rivera-Sanchez, W. W. Busse and W. J. Morgan, “Development and Validation of the Composite Asthma Severity Index—An Outcome Measure for Use in Children and Adolescents,” Journal of Allergy and Clinical Immunology, Vol. 129, No. 3, 2012, pp. 694-701. doi:10.1016/j.jaci.2011.12.962
[9] I. K. Haugen, B. Slatkowsky-Christensen, J. Lessem and T. K. Kvien, “The Responsiveness of Joint Counts, Patient-Reported Measures and Proposed Composite Scores in Hand Osteoarthritis: Analyses from a Placebo-Controlled Trial,” Annals of Rheumatic Diseases, Vol. 69, No. 8, 2010, pp. 1436-1440. doi:10.1136/ard.2008.100156
[10] B. R. Celli, C. G. Cote, J. M. Marin, C. Casanova, M. Montes de Oca, R. A. Mendez, V. P. Plata and H. J. Cabral, “The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index in Chronic Obstructive Pulmonary Disease,” New England Journal of Medicine, Vol. 350, No. 10, 2004, pp. 1005-1012. doi:10.1056/NEJMoa021322
[11] W. J. Taylor, J. A. Singh, K. G. Saag, N. Dalbeth, P. A. MacDonald, N. L. Edwards, L. S. Simon, L. K. Stamp, T. Neogi, A. L. Gaffo, P. P. Khanna, M. A. Becker and H. R. Schumacher, “Bringing It All Together: A Novel Approach to the Development of Response Criteria for Chronic Gout Clinical Trials,” Journal of Rheumatology, Vol. 38, No. 7, 2011, pp. 1467-1470. doi:10.3899/jrheum.110274
[12] N. Schlesinger, R. E. Alten, T. Bardin, H. R. Schumacher, M. Bloch, A. Gimona, G. Krammer, V. Murphy, D. Richard and A. K. So, “Canakinumab for Acute Gouty Arthritis in Patients with Limited Treatment Options: Results from Two Randomised, Multicentre, Active-Controlled, Double-Blind Trials and Their Initial Extensions,” Annals of Rheumatic Diseases, Vol. 71, No. 11, 2012, pp. 1839-1848. doi:10.1136/annrheumdis-2011-200908
[13] J. D. Hirsch, S. J. Lee, R. Terkeltaub, D. Khanna, J. Singh, A. Sarkin, J. Harvey and A. Kavanaugh, “Evaluation of an Instrument Assessing Influence of Gout on Health-Related Quality of Life,” Journal of Rheumatology, Vol. 35, No. 12, 2008, pp. 2406-2414. doi:10.3899/jrheum.080506
[14] J. E. Ware, “SF-36 Health Survey Update,” Spine, Vol. 25, No. 24, 2000, pp. 3130-3139. doi:10.1097/00007632-200012150-00008
[15] M. Kosinski, S. Z. Zhao, S. Dedhiya, J. T. Osterhaus and J. E. Ware, “Determining Minimally Important Changes in Generic and Disease-Specific Health-Related Quality of Life Questionnaires in Clinical Trials of Rheumatoid Arthritis,” Arthritis & Rheumatism, Vol. 43, No. 7, 2000, pp. 1478-1487. doi:10.1002/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M
[16] D. Khanna, A. J. Sarkin, P. P. Khanna, M. M. Shieh, A. F. Kavanaugh, R. A. Terkeltaub, et al., “Minimally Important Differences of the Gout Impact Scale in a Randomized Controlled Trial,” Rheumatology (Oxford), Vol. 50, No. 7, 2011, pp. 1331-1336. doi:10.1093/rheumatology/ker023
[17] B. Bruce and J. F. Fries, “The Stanford Health Assessment Questionnaire: A Review of Its History, Issues, Progress, and Documentation,” Journal of Rheumatology, Vol. 30, No. 1, 2003, pp. 167-178.
[18] A. J. Sarkin, S. R. Tally, T. A. Cronan, G. E. Matt and H. W. Lyons, “Analyzing Attrition in a Community-Based Literacy Program,” Evaluation and Program Planning, Vol. 20, No. 4, 1997, pp. 421-431. doi:10.1016/S0149-7189(97)00023-2

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.